In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform

References

• Aoyama T., Gelboin H. V., Gonzalez F. J. Mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline by complementary DNA-expressed human liver P-450. Cancer Research 1990; 50: 2060–2063
   PubMed Web of Science ®Google Scholar
• Battaglia R., Pianezzola E., Salgarollo G., Zini G., Benedetti M. S. Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man. Journal of Antimicrobial Chemotherapy 1990; 26: 813–822
   PubMed Web of Science ®Google Scholar
• Cocchiara G., Storolin Benedetti M., Vicario G. P., Ballabio M., Gioia B., Vioglio S., Vigevani A. Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica 1989; 19: 769–780
   PubMed Web of Science ®Google Scholar
• Crespi C. L., Penman B. W., Leakey J. A. E., Arlotto M. P., Stark A., Parkinson A., Turner T., Steimel D. T., Rudo K., Davies R. L., Langenbach R. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis 1990; 11: 1293–1300
   PubMed Web of Science ®Google Scholar
• Czerwinski M., McLemore T. L., Philpot R. M., Nhamburo P. T., Korzekwa K., Gelboin H. V., Gonzalez F. J. Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism. Cancer Research 1991; 51: 4636–4638
   PubMed Web of Science ®Google Scholar
• Donato M. T., Gomez-Lechon M. J., Castell J. V. A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. Analytical Biochemistry 1993; 213: 29–33
   PubMed Web of Science ®Google Scholar
• Emori M., Saito H., Saito K., Tomioka H., Setogawa T., Hidaka T. Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. Antimicrobial Agents and Chemotherapy 1993; 37: 722–728
   PubMed Web of Science ®Google Scholar
• Fujii K., Tsuji A., Miyazaki S., Yamaguchi K., Goto S. In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrobial Agents and Chemotherapy 1994; 38: 1118–1122
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J., Korzekwa K. R. Cytochromes P450 expression systems. Annual Review of Pharmacology and Toxicology 1995; 35: 369–390
   PubMed Web of Science ®Google Scholar
• Hosoe K., Konishi E., Hidaka T., Yamane T., Yamashita K., Ohashi T. High-performance liquid chromatographic determination of 3′-hydroxy-5′-(4-isobutyl-1 -piperazinyl)-benzoxazinorifamycin (KRM-1648) and its deacetyl metabolite in plasma, whole blood, urine and tissue samples in rats. Journal of Chromatography B 1994; 653: 177–186
   PubMed Web of Science ®Google Scholar
• Hosoe K., Mae T., Yamashita K., Fujii K., Yamane T., Hidaka T., Ohashi T. Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog. Xenobiotica 1996; 26: 321–332
   PubMed Web of Science ®Google Scholar
• Imai Y., Ito A., Sato R. Evidence for biochemically different types of vesicles in the hepatic microsomal fraction. Journal of Biochemistry 1966; 60: 417–428
   PubMed Web of Science ®Google Scholar
• Imaoka S., Terano Y., Funae Y. Expression of four phenobarbital-inducible cytochrome P-450s in liver, kidney, and lung of rats. Journal of Biochemistry 1989; 105: 939–945
   PubMed Web of Science ®Google Scholar
• Inderlied C. B., Barbara-Burnham L., Wu M., Young L., Bermudez L. Activity of the benzoxazinorifamycin KRM-1648 against the Mycobacterium avium complex in vitro and in macrophages. Antimicrobial Agents and Chemotherapy 1994; 38: 1838–1843
   PubMed Web of Science ®Google Scholar
• Klemens S. P., Grossi M. A., Cynamon M. H. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents and Chemotherapy 1994; 38: 2245–2248
   PubMed Web of Science ®Google Scholar
• Kuze F., Yamamoto T., Amitani R., Suzuki K. In vitro activities of new rifamycin derivatives against mycobacteria. Kekkaku 1991; 66: 7–12
   PubMedGoogle Scholar
• Luna-Herrera J., Reddy M. V., Gangadharam P. R. J. In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrobial Agents and Chemotherapy 1995; 39: 440–444
   PubMed Web of Science ®Google Scholar
• Nelson D. R., Koymans L., Kamataki T., Stegeman J. J., Feyereisen R., Waxman D. J., Waterman M. R., Gotoh O., Coon M. J., Estabrook R. W., Gunsalus I. C., Nerbert D. W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1–42
   PubMedGoogle Scholar
• Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. Journal of Biological Chemistry 1964; 239: 2379–2385
   PubMed Web of Science ®Google Scholar
• Saito H., Tomioka H., Sato K., Emori M., Yamane T., Yamashita K., Hosoe K., Hidaka T. In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrobial Agents and Chemotherapy 1991; 35: 542–547
   PubMed Web of Science ®Google Scholar
• Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Tainaka H., Hatanaka T., Ono S. Use of human P450 expression system in studies of xenobiotic metabolism. Xenobiotic Metabolism and Disposition 1995; 10: 420–425
   Google Scholar
• Tomioka H., Saito H., Sato K., Yamane T., Yamashita K., Hosoe K., Fujii K., Hidaka T. Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrobial Agents and Chemotherapy 1992; 36: 387–393
   PubMed Web of Science ®Google Scholar
• Vigevani A., Ballabio M., Gioia B., Marsili L., Vioglio S., Franceschi G. Identification of urinary metabolites of rifamycin LM 427 in man. Journal of Antibiotics 1985; 38: 1799–1802
   PubMed Web of Science ®Google Scholar
• Yamamoto T., Amitani R., Kuze F., Suzuki K. In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex. Kekkaku 1990; 65: 805–810
   PubMedGoogle Scholar
• Yamane T., Hashizume T., Yamashita K., Konishi E., Hosoe K., Hidaka T., Watanabe K., Kawaharada H., Yamamoto T., Kuze F. Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chemical and Pharmaceutical Bulletin 1993; 41: 148–155
   PubMed Web of Science ®Google Scholar